Bold Therapeutics reaches the 60-patient enrollment midpoint in its Phase 2 trial for BOLD-100, advancing its clinical development pipeline for novel metallotherapeutics.
Bold Therapeutics has achieved a significant clinical milestone by reaching the 60-patient enrollment midpoint for Arm VII of its Phase 2 BOLD-100-001 trial. This progress validates the ongoing development of BOLD-100 as a potential treatment for difficult-to-treat cancers, moving the company closer to its efficacy data readout.
The trial has reached the 60-patient enrollment midpoint for Arm VII.
The company is a clinical-stage biopharmaceutical firm developing novel metallotherapeutics for difficult-to-treat cancers.
Vancouver-based Bold Therapeutics has reached the halfway point in Arm VII of its Phase 2 BOLD-100-001 clinical trial. The study evaluates the efficacy of BOLD-100 in treating difficult-to-treat cancers, marking a significant operational milestone for the biopharmaceutical firm.
Reaching the 60-patient mark represents the enrollment midpoint for Arm VII of the Phase 2 BOLD-100-001 trial, signaling steady progress in the company's clinical development timeline.